STEHealthcare · Medical DevicesThe 8 Wall Street analysts covering STERIS Plc (Ireland) hold a median 12-month price target of $269 — +8.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores STERIS Plc (Ireland) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Momentum (43): The shares have been drifting down relative to others.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on STE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.4% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $270 → $275 |
| 7 Aug 2026 | UBS | Maintains | Buy | $275 → $270 |
| 28 July 2026 | UBS | Initiates | Buy | — |
| 28 July 2026 | UBS | Initiates | Buy | $275 |
| 13 May 2026 | Keybanc | Maintains | Overweight | — |
| 13 May 2026 | Keybanc | Maintains | Overweight | $291 → $269 |
| 8 Aug 2025 | Morgan Stanley | Maintains | Overweight | — |
| 22 July 2025 | Keybanc | Maintains | Overweight | — |
| 15 July 2025 | Morgan Stanley | Upgrade | Overweight | — |
| 29 May 2025 | Jefferies | Initiates | Hold | — |
| 19 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 16 May 2025 | JMP Securities | Maintains | Market Outperform | — |
| 15 May 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 12 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 7 Apr 2025 | Needham | Reiterates | Hold | — |
| 6 Feb 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 6 Feb 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 3 Feb 2025 | Piper Sandler | Maintains | Overweight | — |
| 18 Nov 2024 | JMP Securities | Reiterates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
STE appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, STERIS Plc (Ireland) returned +3.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 27% of US stocks
Cheaper than 31% of US stocks
Cheaper than 29% of US stocks
Cheaper than 23% of US stocks
Higher than 46% of US stocks
Higher than 52% of US stocks
Higher than 57% of US stocks
Higher than 78% of US stocks
Higher than 75% of US stocks
Higher than 66% of US stocks
Higher than 84% of US stocks
Higher than 73% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
STERIS Plc (Ireland) has a market value of $22.8B and an enterprise value of $24.3B.
Revenue in the twelve months to 30 June 2026: $6.0B. The latest quarter grew 7.3% year on year.
Net income over the same four quarters: $808.1M, a 13.4% net margin.
Diluted earnings per share, trailing twelve months: $8.18.
Free cash flow in the twelve months to 30 June 2026: $925.6M.
STERIS Plc (Ireland) spent $340.4M on share buybacks and $247.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 28.3×; forward P/E: 18.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.19%, paying out 31% of earnings.
STERIS Plc (Ireland) employs 17,937 people — $337K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own STERIS Plc (Ireland) — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Steris’s Q2 revenue and EPS offer a view of its performance for the quarter ended September 2026, and highlights comparing key metrics with Wall Street estimates and year-ago figures.
Why it matters — These comparisons provide STE watchers additional context for assessing quarterly results.
Steris reported quarterly earnings of $2.94 per share, above the Zacks Consensus Estimate of $2.67. Earnings were $2.47 per share in the same period a year ago.
Why it matters — The reported earnings exceeded estimates and were higher than a year earlier, giving STE watchers an update on quarterly results.
STERIS reported fiscal 2027 second-quarter revenue of $1.6 billion, up 9% from $1.5 billion a year earlier. Constant-currency organic revenue growth was 8%.
Why it matters — The results provide STE watchers with an update on the company’s quarterly revenue and organic growth.
A Zacks Investment Research article says STERIS's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons, and continued margin expansion.
Why it matters — These factors are highlighted as potential influences on the upcoming quarterly results that STE watchers may follow.
Zacks Investment Research highlights GMED and STERIS (STE) as healthcare technology stocks positioned for growth, citing projected 2026 EPS gains, valuations, and innovations in essential medical services.
Why it matters — The item frames STERIS as a company offering exposure to healthcare technology growth and points to its projected 2026 EPS gains and innovations.
The 8 Wall Street analysts covering STERIS Plc (Ireland) have a median 12-month price target of $269, with estimates ranging from $232 to $275. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering STERIS Plc (Ireland), 5 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks STERIS Plc (Ireland) 90 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, STERIS Plc (Ireland) ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +8.4% from the last close, and Ticker Nerd's factor model ranks STERIS Plc (Ireland) 90 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering STERIS Plc (Ireland) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $232 to $275 over the next 12 months.
STERIS Plc (Ireland) returned +3.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
STERIS plc is a healthcare and life sciences company that provides infection prevention, contamination control, and procedural products and services. The company offers a broad portfolio that includes sterilizers, surgical tables, endoscopy accessories, cleaning chemistries, instrument and scope repair, laboratory testing, and outsourced reprocessing services.
The most recent item we track (Zacks Investment Research, 5 Nov 2026): "Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics". Zacks Investment Research says Steris’s Q2 revenue and EPS offer a view of its performance for the quarter ended September 2026, and highlights comparing key metrics with Wall Street estimates and year-ago figures.
STERIS plc is a healthcare and life sciences company that provides infection prevention, contamination control, and procedural products and services. The company offers a broad portfolio that includes sterilizers, surgical tables, endoscopy accessories, cleaning chemistries, instrument and scope repair, laboratory testing, and outsourced reprocessing services. Its operations support hospitals, ambulatory surgery centers, pharmaceutical and medical device manufacturers, and research laboratories. STERIS plc also serves biopharmaceutical and life sciences customers with contamination-control equipment, sterilization technologies, and related maintenance services. Through its mix of consumables, capital equipment, and recurring service offerings, the company plays an important role in helping healthcare and production environments maintain sterile conditions and support patient care across global markets.
CEO Mr. Daniel A. Carestio · 17,937 employees · United States · https://www.steris.com
